N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity

International Journal of Cardiology

Volumn 173, Issue 2, 2014, Pages 154-162

  Alencar, Allan K N ^a   Pereira, Sharlene L ^a   Da Silva, Flavia E ^a   Mendes, Luiza V P ^a   Cunha, Valéria Do M N ^a   Lima, Lidia M ^a   Montagnoli, Tadeu L ^a   Caruso Neves, Celso ^a   Ferraz, Emanuelle B ^a   Tesch, Roberta ^a   Nascimento, José H M ^a   Sant'Anna, Carlos M R ^b   Fraga, Carlos A M ^a   Barreiro, Eliezer J ^a   Sudo, Roberto T ^a   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

A2A adenosine agonist; Monocrotaline; N acylhydrazone derivative; Pulmonary hypertension; Pulmonary vascular remodeling; Ventricular dysfunction

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE TRIPHOSPHATASE (CALCIUM); ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRAZONE DERIVATIVE; MONOCROTALINE; N (3,4 DIMETHOXYBENZYLIDENE) 4 METHOXYBENZOHYDRAZIDE; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; BENZAMIDE DERIVATIVE; NOS3 PROTEIN, RAT; N′-(3,4-DIMETHOXYBENZYLIDENE)-4-METHOXYBENZOHYDRAZIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEART VENTRICLE FAILURE; LUNG PARENCHYMA; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RAT; REGULATORY MECHANISM; SYSTOLIC BLOOD PRESSURE; TREADMILL TEST; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ECHOGRAPHY; EXERCISE TOLERANCE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PULMONARY ARTERY; VASODILATATION; WISTAR RAT;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; BENZAMIDES; EXERCISE TOLERANCE; HYDRAZONES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY ARTERY; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; VASODILATION;

EID: 84898896224     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.02.022     Document Type: Article

References (39)

1. R.S. Baliga, R.J. MacAllister, and A.J. Hobbs New perspectives for the treatment of pulmonary hypertension Br J Pharmacol 163 2011 125 140
2. S.L. Archer, K. Djaballah, and M. Hubert et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension Am J Respir Crit Care Med 158 1998 1061 1067
3. R.T. Schermuly, H.A. Ghofrani, R.M. Wilkins, and F. Grimminger Mechanisms of disease: pulmonary arterial hypertension Nat Rev Cardiol 8 2011 443 455
4. L.Q. Bi, R. Zhu, and H. Kong et al. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats Int Immunopharmacol 16 2013 7 16
5. W. Janssen, R.T. Schermuly, and B. Kojonazarov The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload Exp Physiol 98 8 2013 1274 1278
6. L.J. Rubin, G. Simonneau, and D. Badesch et al. The study of risk in pulmonary arterial hypertension Eur Respir Rev 21 125 2012 234 238
7. J.C. Shryock, and L. Belardinelli Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology Am J Cardiol 79 12A 1997 2 10
8. 2A subtype receptor agonists Br J Pharmacol 144 2005 642 650
9. A.M. Feldman, E. Cheksis-Feiner, E. Hamad, and T. Chan Adenosine receptor subtypes and the heart failure phenotype: translating lessons from mice to man Trans Am Clin Climatol Assoc 122 2011 198 214
10. 2A receptor on monocrotaline-induced pulmonary hypertension in rats Br J Pharmacol 169 2013 953 962
11. G. Zapata-Sudo, L.B. Pontes, and J.S. Silva et al. Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model Eur J Pharmacol 690 2012 176 182
12. 2 + channel antagonista reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonar hypertension Eur J Pharmacol 702 2013 316 322
13. 2A receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2 Neurotox Res 22 2012 150 157
14. 2A adenosine receptor bound to an antagonist Science 322 5905 2008 1211 1217
15. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J Mol Biol 267 3 1997 727 748
16. A.D. Becke Density-functional thermochemistry. V. Systematic optimization of exchange-correlation functionals J Chem Phys 107 1997 8554 8561
17. R.M. Lang, M. Bierig, and R.B. Devereux et al. Recommendations for chamber quantification Eur J Echocardiogr 7 2006 79 108
18. S.S. Landgraf, M. Wengert, and J.S. Silva et al. Changes in angiotensin receptors expression play a pivotal role in the renal damage observed in spontaneously hypertensive rats Am J Physiol Renal Physiol 300 2 2011 499 510
19. 2 +-ATPases of Saccharomyces cerevisiae: diversity and possible role in protein sorting FEMS Microbiol Lett 162 1998 83 91
20. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
21. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of 6 bacteriophage T4 Nature 227 1970 680 685
22. 2 + homeostasis in rat vas deferens J Pharmacol Toxicol Methods 47 2002 93 98
23. S. Schrolla, D. Sebaha, M. Wagnera, V. Poparaa, M. Pfeifer, and F. Blumberg Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil Respir Physiol Neurobiol 186 2013 61 64
24. R.T. Schermuly, E. Dony, and H.A. Ghofrani et al. Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 10 2005 2811 2821
25. N. Galiè, B.H. Brundage, and H.A. Ghofrani et al. Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
26. N. Galiè, H.A. Ghofrani, and A. Torbicki et al. Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
27. A receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials J Cardiovasc Pharmacol 44 2004 S80 S84
28. J.W. Koskenvuo, R. Mirsky, and Y. Zhang et al. A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model Int J Cardiovasc Imaging 26 2010 509 518
29. T.K. Jeffery, and J.C. Wanstall Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension Pharmacol Ther 92 2001 1 20
30. T.T. Zhang, B. Cui, D.Z. Dai, and W. Su CPU 86017, p- chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway Acta Pharmacol Sin 26 11 2005 1309 1316
31. 2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice J Vasc Res 48 2011 171 183
32. +-ATPase and potassium channels Pharmacol Rep 57 2005 824 832
33. (2B) receptor for 2-(1-hexynyl)adenosine Mol Pharmacol 58 6 2000 1349 1356
34. Y. Pei, P. Ma, and X. Wang et al. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism Eur J Pharmacol 666 2011 165 172
35. M. Sahara, M. Sata, T. Morita, Y. Hirata, and R. Nagai Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension PLoS One 7 3 2012 e33367
36. G. Walford, and J. Loscalzo Nitric oxide and vascular biology J Thromb Haemost 1 2003 2112 2118
37. D.B. Badesch, G.E. Raskob, and C.G. Elliott et al. Pulmonary arterial hypertension baseline characteristics from the reveal registry Chest 137 2 2010 376 387
38. 1-adenosine receptor Clin Transl Sci 1 2 2008 126 133 [10]
39. Y. Yang, Y. Mou, S.J. Hu, and M. Fu Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins Eur J Heart Fail 11 2009 6 13